Pharma BD Deal Intelligence

Ensho Therapeutics, Inc. / EA Pharma Co., Ltd.

2024 · Licensing/Option · Complete

EA Pharma granted Ensho Therapeutics an exclusive worldwide license (excluding Japan, China, Hong Kong, Macau, South Korea, Taiwan and ASEAN) to develop and commercialize EA1080, an oral selective alpha4beta7 integrin antagonist, and a related portfolio of oral integrin antagonists for inflammatory bowel disease. Ensho will run global clinical trials in collaboration with EA Pharma and plans to start Phase 2 development in the first half of 2025; EA Pharma is eligible for development, regulatory and commercial milestones plus tiered royalties up to a low double-digit percentage of net sales. Total deal value was not disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2029 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2024 deals